Inicio>>Signaling Pathways>> Cardiovascular>> Arrhythmia>>Pirmenol

Pirmenol (Synonyms: (±)-Pirmenol)

Catalog No.GC47960

A class I antiarrhythmic agent

Products are for research use only. Not for human use. We do not sell to patients.

Pirmenol Chemical Structure

Cas No.: 68252-19-7

Tamaño Precio Disponibilidad Cantidad
1 mg
49,00 $
Disponible
5 mg
211,00 $
Disponible
10 mg
374,00 $
Disponible
25 mg
806,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Pirmenol is a class I antiarrhythmic agent.1,2,3 It lengthens the final repolarization of action potentials in isolated rabbit ventricular myocytes and inhibits tachyarrhythmias induced by prolonged afterdepolarizations in isolated guinea pig papillary muscles when used at a concentration of 5 µM.1 Pirmenol (2.5 and 5 mg/kg) suppresses ouabain- or epinephrine-induced ventricular arrhythmias and aconitine-induced atrial arrhythmias in dogs.2,3

1.Sawanobori, T., Adaniya, H., Yamashita, S., et al.Electrophysiologic and antiarrhythmic actions of pirmenol on rabbit and guinea pig cardiac preparationsJ. Cardiovasc. Pharmacol.16(6)975-983(1990) 2.Kaplan, H.R., Mertz, T.E., and Steffe, T.J.Preclinical pharmacology of pirmenolAm. J. Cardiol.59(16)2H-9H(1987) 3.Steffe, T.J., Mertz, T.E., Hastings, S.G., et al.CL-845 (pirmenol hydrochloride): A new orally effective long-acting antiarrhythmic agentJ. Pharmacol. Exp. Ther.214(1)50-57(1980)

Reseñas

Review for Pirmenol

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pirmenol

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.